Stock Analysis
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
BioMarin Pharmaceutical Inc. (BMRN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
BioMarin Pharmaceutical Inc. (BMRN) currently has an AIQ Score of 48/100, indicating a neutral setup. Sentiment is the strongest factor at 69/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BMRN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $58.51 |
| AIQ Score | 48/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $12.53B |
| P/E Ratio (TTM) | 170.63 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.23 |
| Revenue (quarter ended 2026-06-30) | $989.71M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.23 |
| Volume | 2.27M |
| 52-week range | $49.26-$70.98 |
| RSI 14 | 60.78 |
| 50-Day SMA | $60.80 |
| 200-Day SMA | $58.42 |
| Analyst Price Target | $93.04 |
| Next Earnings | Nov 2, 2026 |
BMRNBioMarin Pharmaceutical Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum52
- Value38
- Quality51
- Risk resilience54
- Sentiment69
BMRN Stock Analysis Summary
BioMarin Pharmaceutical Inc. (BMRN) currently has an AIQ Score of 48/100, indicating a neutral setup. Sentiment is the strongest factor at 69/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BMRN has AIQ Score of 48/100 with Sentiment base of 69/100 and fading Value at 38/100. Wait for component alignment before adding exposure.
Sentiment (69/100) leads while Value (38/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.77% stock move · BMRN classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BMRN Bullish or Bearish Right Now?
BMRN currently has a neutral overall setup. Sentiment is the strongest factor at 69/100, while Value is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +59.02% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (22 vs 20).
- - Value is the current constraint at 38/100.
- - Price is -1.60% below its 200-day SMA.
Current Consensus
BMRN's Technical Analysis Consensus is currently Neutral, with 22 buy, 3 neutral, and 20 sell votes. BMRN's 14-day RSI is 60.78, which places the stock in a constructive momentum range. BMRN's beta is 0.23, indicating lower market sensitivity than the broad market.
What Changed in BMRN?
The largest recent change in BMRN is Momentum moving up by 11.0 points over the available 7-day comparison window. Sentiment remains the strongest visible factor.
What Would Change the BMRN Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BMRN Decision Framework
Public evidence layers, setup checks, and risk context for BioMarin Pharmaceutical Inc..
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
BioMarin Pharmaceutical Inc. has an AIQ Score of 48/100 in a Neutral regime. Sentiment is strongest at 69/100. Beta is 0.22, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BMRN is in a Neutral AIQ regime with score 48/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 69/100 while value lags at 38/100. |
| Factor Evidence | Momentum 52/100 · Value 38/100 · Quality 51/100 · Risk 54/100 · Sentiment 69/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 69/100.
Momentum is 52/100 and RSI (14) is 60.8.
BMRN is in a Neutral regime at 48/100.
Risk factor is 54/100 with beta 0.22 and annual volatility 35.36%.
Current conflict: sentiment leads at 69/100 while value lags at 38/100.
BMRN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BMRN Fundamentals
BMRN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BMRN Technical Analysis
BMRN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BMRN Stock Catalysts
Track BMRN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BMRN Dividend Analysis
BMRN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BMRN Financial Data
BMRN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BMRN Risk Analysis
BMRN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BMRN Stock News
BMRN stock news, market tone, recent headlines, and catalyst context.
BMRN vs Large Cap Pharma Peers
Current peer cohort: BMRN · BMY · BNTX · GILD · GSK. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BMRN Current stock | 48/100 | 38/100 | 52/100 | 54/100 | 0.35 | 35.36% | Current |
| BMY Bristol-Myers Squibb | 61/100 | 65/100 | 55/100 | 41/100 | 1.3 | 28.39% | BMRN vs BMY |
| BNTX BioNTech | 45/100 | 35/100 | 27/100 | 65/100 | -0.17 | 46.86% | BMRN vs BNTX |
| GILD Gilead Sciences | 47/100 | 37/100 | 81/100 | 44/100 | 1.23 | 27.06% | BMRN vs GILD |
| GSK GSK | 62/100 | 67/100 | 51/100 | 46/100 | 0.2 | 25.98% | BMRN vs GSK |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BMRN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BMRN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BMRN Stock FAQ
What is BMRN stock price today?
BioMarin Pharmaceutical Inc.'s current stock price is $58.51. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BMRN bullish or bearish right now?
BMRN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BMRN's market cap?
BMRN's market cap is $12.53B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BMRN's current P/E ratio?
BMRN's current P/E ratio is 170.63 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BMRN's RSI?
BMRN's 14-day RSI is 60.78 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BMRN above its 50-day and 200-day moving averages?
BMRN is -5.44% from its 50-day SMA and -1.60% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BMRN's next earnings date?
BMRN's next earnings date is currently listed as Nov 2, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BMRN pay a dividend?
BMRN's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.